EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis

Qiwei Yang, Lin Yu, Yishan Peng, Qing Yuan, Ning Fan, Genshu Wang

Journal of Hepatocellular Carcinoma · 2026-07 · Volume 13 · 1-18

DOI: 10.2147/jhc.s627971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-07. Verfasst von Qiwei Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic reprogramming has emerged as a critical hallmark and promising therapeutic target in primary liver cancer (PLC), including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). However, the global research landscape, collaboration patterns, and evolving hotspots of metabolism-targeted therapeutic strategies in PLC remain unclear.

Methods

Publications related to metabolic reprogramming and therapeutic strategies in PLC published between 2005 and 2025 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric and visualization analyses were performed using VOSviewer, CiteSpace, and RStudio to evaluate publication trends, collaborative networks, co-cited references, and keyword evolution.

Results

A total of 1,316 publications involving 9,216 authors from 1,805 institutions across 62 countries/regions were included. China contributed the largest number of publications, whereas the United States demonstrated the strongest citation influence. Current research mainly focuses on metabolic reprogramming involving glucose, lipid, and amino acid metabolism, as well as tumor microenvironment-associated metabolic alterations in PLC. Keyword burst and clustering analyses indicated increasing attention toward immunotherapy resistance, tumor microenvironment remodeling, and metabolism-based combination therapies. Collaborative network analysis revealed active international cooperation, particularly between China and the United States.

Conclusion

Research on metabolism-targeted therapeutic strategies for PLC has expanded rapidly over the past two decades. Current hotspots mainly involve metabolic reprogramming and tumor microenvironment-associated therapeutic approaches. These findings provide a comprehensive overview of the evolving research landscape and may facilitate future mechanistic investigations and translational therapeutic development in PLC.

Schlagwörter

Stichwörter der Autor:innen

bibliometric analysis hotspotsmetabolic inhibitorsmetabolic reprogrammingprimary liver cancertumor microenvironment

Autor:innen und Institutionen

  • The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • State Key Laboratory of Traditional Chinese Medicine Syndrome; Department of Liver Transplant and Surgery of Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Engineering Research Center of Precisi…

Zitieren

APA

Yang, Q., Yu, L., Peng, Y., Yuan, Q., Fan, N., & Wang, G. (2026). Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis. Journal of Hepatocellular Carcinoma, Volume 13, 1-18. https://doi.org/10.2147/jhc.s627971

Vancouver

Yang Q, Yu L, Peng Y, Yuan Q, Fan N, Wang G. Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-18. doi:10.2147/jhc.s627971

BibTeX
@article{Yang2026,
  author = {Yang, Qiwei and Yu, Lin and Peng, Yishan and Yuan, Qing and Fan, Ning and Wang, Genshu},
  title = {Metabolic Reprogramming-Targeted Therapeutic Strategies in Primary Liver Cancer: A Bibliometric and Visualized Analysis},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--18},
  doi = {10.2147/jhc.s627971}
}
Kostenlos starten →